克拉屈滨治疗毛细胞白血病:30年长期缓解经验
一线治疗总反应率86%、完全缓解率44%;一线克拉屈滨治疗者反应率86%、完全缓解率54%,中位至下次治疗时间8.2年,部分缓解者显著短于完全缓解者。
要点
- 一线克拉屈滨治疗毛细胞白血病总反应率86%,完全缓解率54%。
- 完全缓解者中68%未再治疗,部分持续缓解超过20年。
- 部分缓解者中位至下次治疗时间显著短于完全缓解者。
核心结论
- 嘌呤类似物克拉屈滨一线及再治疗均能获得较高反应率。
- 部分患者单疗程克拉屈滨后可获得长期无治疗间隔。
研究设计与样本
- 反应分类结合共识标准与骨髓免疫组化,按治疗线数分组。
主要发现
- 一线治疗总反应率86%,完全缓解率44%。
- 第二至第四线治疗反应率分别为84%、81%、79%,完全缓解率分别为38%、37%、15%。
- 66例完全缓解者中45例(68%)未再治疗,持续完全缓解5-10年11例、10-20年14例、超过20年3例。
- 一线克拉屈滨治疗者中位至下次治疗时间8.2年,部分缓解者5.3年 vs 完全缓解者未达到(25.8年时),p < 0.001。
临床怎么用
- 克拉屈滨可作为毛细胞白血病一线治疗选择。
- 完全缓解者可能获得长期无治疗间隔,需长期随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The treatment of hairy cell leukemia (HCL) has considerably changed over years. Purine analogues, namely cladribine, now represent the treatment of choice. One hundred and eighty-four patients were followed between 1986 and 2018 and treated according to era-specific guidelines. Responses were classified by combining Consensus Resolution criteria and marrow immunohistochemistry. Patients were grouped according to the number of treatment lines they received. Patients treated first line responded in 86% of cases, with complete response (CR) in 44% of cases. Response rates remained high throughout the first four lines (84%, 81%, 79% for the second line onward, with CR in 38%, 37%, 15% of cases respectively). One hundred and twenty-two patients received cladribine as first line treatment, with a response rate of 86% and a CR rate of 54%. Among the 66 CR patients, 45 (68%) have never received further therapy: 11 patients are in continuous CR between 5 and 10 years after treatment, 14 between 10 and 20 years and three patients at more than 20 years. Median time-to-next treatment (TTNT) for frontline cladribine-treated patients was 8.2 years: partial responders had a significantly shorter median TTNT than CR patients (5.3 years vs median not reached at 25.8 years, p < 0.001). Patients with HCL require subsequent lines of therapy in more than 50% of cases. Purine analogues allow significant response rates when applied first line and upon retreatment. Some patients may enjoy long lasting treatment-free intervals after one course of cladribine.
引用
- Broccoli A, Argnani L, Nanni L, et al. The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience. Am J Hematol. 2021. PMID: 34245477. doi:10.1002/ajh.26287
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。